Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA)
- DVA Medical Center, Ann Arbor, MI (United States)
- Immunomedics Inc., Morris Plains, NJ (United States); and others
We conducted a Phase II prospective multicenter clinical trial to investigate the safety and efficacy of Tc-99M anti-CEA Fab`(ImmuRAID-CEA) in patients with non-small cell lung cancer. Fifty four patients (42 male; 12 female; age range 40-93 yr) had primary operable (19), primary inoperable (7), occult (9), metastatic (15) or recurrent (4) disease. Patients were injected with 1 mg ImmuRAID-CEA radiolabeled with 20-30 mCi Tc-99m pertechnetate and imaged at 4-8 and 18-24 hr by planar and SPECT techniques; ten were imaged at 15-18 hr only. Despite prominent blood pool activity at 4-8 hr. overall imaging statistics on a per patient basis revealed a sensitivity of tumor detection of 90%, accuracy 85% and positive predictive value 94%. The later images had lower count rates but target to background ratios were improved. On a per lesion basis, sensitivity in the chest was 69% and in liver 88%. Twenty four patients had additional foci of antibody uptake at sites previously believed to be uninvolved; cancer was confirmed in 11, not confirmed in 2 and currently indeterminate in 11. Furthermore, a negative scan confirmed equivocal radiographic studies as true negative in 5 patients. With respect to safety, there were no adverse clinical reactions and four minor, transient changes in hematologic and/or biochemical parameters. Human anti-mouse antibody (HAMA) determinations on 27 patients using ImmuSTRIP{reg_sign} HAMA Fragment assay were negative at 4-6 weeks or 3 months post-infusion. We conclude that imaging with ImmuRAID-CEA is safe and potentially useful for the evaluation and staging of lung cancer patients.
- OSTI ID:
- 198073
- Report Number(s):
- CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0225
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Iodine-131 labeled anti-CEA polyclonal antibody detection of gastrointestinal cancer
Evaluation of primary lung cancer with indium 111 anti-carcinoembryonic antigen (type ZCE-025) monoclonal antibody scintigraphy